Results 111 to 120 of about 7,693 (199)

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells [PDF]

, 2016
BACKGROUND: Anti-apoptotic BCL-2 family members antagonise apoptosis by sequestering their pro-apoptotic counterparts. The balance between the different BCL-2 family members forms the basis of BH3 profiling, a peptide-based technique used to predict ...
Butterworth, Michael, Cohen, Gerald M, Pettitt, Andrew, Varadarajan, Shankar   +3 more
core   +1 more source

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37

Data in Brief, 2016
Unfortunately, the mutagenic activities of chemotherapy and radiotherapy can provoke development of therapy-induced malignancies in cancer survivors. Non-mutagenic anti-cancer therapies may be less likely to trigger subsequent malignant neoplasms.
Maja M. Green, Tanmay M. Shekhar, Christine J. Hawkins   +2 more
doaj   +1 more source

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming. [PDF]

, 2016
The impact of EGFR-mutant NSCLC precision therapy is limited by acquired resistance despite initial excellent response. Classic studies of EGFR-mutant clinical resistance to precision therapy were based on tumor rebiopsies late during clinical tumor ...
Bagai, Rakesh, Bivona, Trever G, Danielpour, David, Feng, Yan, Leahy, Patrick, Lindner, Daniel, Ma, Patrick C, Rosell, Rafael, Shi, Ivy, Thiagarajan, Praveena S, Veigl, Martina, Wu, Xiaoliang, Yin, Lihong, Zhang, Wei, Zhang, Zhenfeng   +14 more
core   +1 more source

Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma

International Journal of Molecular Sciences
Mucinous epithelial ovarian cancer (mEOC) is a rare subtype of epithelial ovarian cancer, characterized by poor responses to standard platinum-based chemotherapy. Polo-like kinase 1 (PLK1) is a key regulator of mitosis and cell cycle progression and its inhibition has been recently identified as a target in mEOC.
Serena Petrella, Marika Colombo, Mirko Marabese, Chiara Grasselli, Andrea Panfili, Michela Chiappa, Valentina Sancisi, Ilaria Craparotta, Maria C. Barbera, Giada A. Cassanmagnago, Marco Bolis, Giovanna Damia   +11 more
openaire   +2 more sources

A inibição da MPS-1 combinada com um indutor da apoptose potencializa a atividade antitumoral em cultural 2D e 3D de células de cancro do pulmão

RevSALUS, 2022
Bárbara Fernandes Pinto, Patrícia M. A. Silva, Juliana Carvalho Tavares, Hassan Bousbaa   +3 more
doaj   +1 more source

Potentiation Of The Nasopharyngeal Carcinoma Cell Lines By Maritoclax To Abt-263 In 2-Dimensional And 3-Dimensional Cell Culture Methods [PDF]

, 2017
Malaysia mempunyai kes kanser nasofarinks, lebih dikenali sebagai kanser pangkal hidung, yang tertinggi di dunia. Kanser nasofarinks merupakan sejenis kanser yang boleh diubati jika dirawat pada peringkat awal Malaysia has one of the highest ...
Lian, Benedict Shi Xiang
core  

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies

Journal of Hematology & Oncology
Background Small molecule inhibition of BCL-XL with navitoclax resulted in on-target dose-limiting thrombocytopenia. DT2216 was more effective than navitoclax and reduced platelet toxicity in preclinical models by selectively degrading BCL-XL via the VHL
Daruka Mahadevan, Minal Barve, Devalingam Mahalingam, Jay Parekh, Michael Kurman, James Strauss, Larry Tremaine, Robert Hromas, Joshua Sills, John McCulloch, John Harkey, Stacy Suberg, Lisa Zimmerman, Guangrong Zheng, Daohong Zhou   +14 more
doaj   +1 more source

Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer

Neoplasia: An International Journal for Oncology Research
Resistance to mitochondrial apoptosis is a major driver of chemoresistance in pancreatic ductal adenocarcinoma (PDAC). However, pharmacological manipulation of the mitochondrial apoptosis threshold in PDAC cells remains an unmet therapeutic goal.
Travis Vander Steen, Ingrid Espinoza, Cristina Duran, Guillem Casadevall, Eila Serrano-Hervás, Elisabet Cuyàs, Sara Verdura, George Kemble, Scott H. Kaufmann, Robert McWilliams, Sílvia Osuna, Daniel D. Billadeau, Javier A. Menendez, Ruth Lupu   +13 more
doaj   +1 more source

A human neuron Alzheimer’s disease model reveals barriers to senolytic translatability

Alzheimer’s Research & Therapy
Therapeutic successes in mouse models of Alzheimer’s disease (AD) largely fail to translate into clinical trials, with experimental drugs rarely validated in human models before being administered to humans.
Chaska C. Walton, Ellen Wang, Suckwon Lee, Cynthia J. Siebrand, Nicholas J. Bergo, Zachary Mayeri, Julie K. Andersen   +6 more
doaj   +1 more source

Navitoclax [PDF]

, 2020
openaire   +1 more source